{"id":"recombinant-flt3-ligand","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Splenomegaly"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Flt3 Ligand is a cytokine that acts as a growth factor for early hematopoietic cells. By engaging the Flt3 receptor on bone marrow progenitors, it promotes expansion of multiple cell lineages including dendritic cells, which can enhance immune responses. This mobilization of immune cells has been explored therapeutically in cancer immunotherapy and hematopoietic recovery contexts.","oneSentence":"Recombinant Flt3 Ligand stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells by binding to the Flt3 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:28.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (in combination with other agents)"},{"name":"Hematopoietic stem cell mobilization"}]},"trialDetails":[{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT05029999","phase":"PHASE1","title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-20","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT02839265","phase":"PHASE2","title":"FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-07","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":33},{"nctId":"NCT06439199","phase":"","title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":60},{"nctId":"NCT03329950","phase":"PHASE1","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2017-12-01","conditions":"Melanoma, Non-small Cell Lung Cancer, Breast Cancer","enrollment":132},{"nctId":"NCT00019396","phase":"PHASE2","title":"flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1998-02","conditions":"Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer","enrollment":""},{"nctId":"NCT04491084","phase":"PHASE1, PHASE2","title":"FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2021-01-01","conditions":"Non Small Cell Lung Cancer, Lung Cancer","enrollment":5},{"nctId":"NCT03789097","phase":"PHASE1, PHASE2","title":"Vaccination With Flt3L, Radiation, and Poly-ICLC","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-04-05","conditions":"Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":56},{"nctId":"NCT01976585","phase":"PHASE1, PHASE2","title":"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy","status":"COMPLETED","sponsor":"Joshua Brody","startDate":"2014-01-03","conditions":"Low-Grade B-cell Lymphoma","enrollment":21},{"nctId":"NCT02129075","phase":"PHASE2","title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-09","conditions":"Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary","enrollment":60},{"nctId":"NCT04641910","phase":"","title":"Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2021-06-08","conditions":"Acute Myeloid Leukemia","enrollment":201},{"nctId":"NCT01470638","phase":"","title":"A Study of Flt3-Ligand Levels in Sjögrens Syndrome","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2009-06","conditions":"Sjogrens Syndrome","enrollment":30},{"nctId":"NCT02693899","phase":"","title":"Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2016-05-27","conditions":"Acute Leukemia","enrollment":80},{"nctId":"NCT01624701","phase":"PHASE1, PHASE2","title":"Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells","status":"TERMINATED","sponsor":"Singapore General Hospital","startDate":"2012-03","conditions":"Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome","enrollment":3},{"nctId":"NCT00020540","phase":"PHASE1","title":"Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-03","conditions":"Kidney Cancer, Melanoma (Skin)","enrollment":""},{"nctId":"NCT01921998","phase":"","title":"Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy","status":"SUSPENDED","sponsor":"The Christie NHS Foundation Trust","startDate":"2013-10","conditions":"Lymphoma, Sarcoma","enrollment":50},{"nctId":"NCT00006223","phase":"PHASE3","title":"flt3L in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-07","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00003431","phase":"PHASE1","title":"Flt3L in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"1998-06","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":""},{"nctId":"NCT00006225","phase":"PHASE1, PHASE2","title":"Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1999-11","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00005787","phase":"PHASE1","title":"Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"1999-09","conditions":"Lymphoma, Neutropenia","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CDX-301","FLT 3 Ligand","FLT3 Ligand","Flt3-Ligand","Flt3L"],"phase":"phase_3","status":"active","brandName":"Recombinant Flt3 Ligand","genericName":"Recombinant Flt3 Ligand","companyName":"University of Southern California","companyId":"university-of-southern-california","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombinant Flt3 Ligand stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells by binding to the Flt3 receptor. Used for Cancer immunotherapy (in combination with other agents), Hematopoietic stem cell mobilization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}